Abpro Holdings, Inc. SEC filings ABPWW
Abpro Holdings, Inc. has 253 filings in SEC EDGAR's recent list, going back to Dec 2, 2021. Its latest annual report, Form 10-K, was filed on Apr 15, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 1, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 25-NSE | Delisting notice | Sep 30, 2026 | — |
| NT 10-Q | Notification of late filing | May 15, 2026 | Mar 31, 2026 |
| NT 10-K | Notification of late filing | Mar 31, 2026 | Dec 31, 2025 |
| EFFECT | Filing | Dec 2, 2025 | — |
| CORRESP | Letter to the SEC | Dec 2, 2025 | — |
| EFFECT | Filing | Jun 12, 2025 | — |
| CORRESP | Letter to the SEC | Jun 10, 2025 | — |
| CORRESP | Letter to the SEC | Jun 6, 2025 | — |
| UPLOAD | Letter from the SEC | May 30, 2025 | — |
| EFFECT | Filing | May 5, 2025 | — |
| POS EX | Post-effective amendment no. 1 to form s-1 | Apr 23, 2025 | — |
| NT 10-K | Notification of late filing | Apr 1, 2025 | Dec 31, 2024 |
| EFFECT | Filing | Feb 12, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 7, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 3, 2025 | — |
| NT 10-Q | Notification of late filing | Nov 15, 2024 | Sep 30, 2024 |
| 25-NSE | Delisting notice | Nov 12, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 8, 2024 | — |
| 425 | Filing | Nov 6, 2024 | — |
| 425 | Filing | Nov 4, 2024 | — |
| SEC STAFF LETTER | Filing | Oct 24, 2024 | — |
| 425 | Filing | Oct 21, 2024 | — |
| EFFECT | Filing | Oct 18, 2024 | — |
| CORRESP | Letter to the SEC | Oct 16, 2024 | — |
| 425 | Filing | Oct 15, 2024 | — |
| CORRESP | Letter to the SEC | Oct 9, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 19, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 5, 2024 | — |
| 425 | Filing | Sep 4, 2024 | — |
| CORRESP | Letter to the SEC | Sep 3, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 30, 2024 | — |
| 425 | Filing | Aug 29, 2024 | — |
| NT 10-Q | Filing | Aug 14, 2024 | Jun 30, 2024 |
| 425 | Filing | May 31, 2024 | — |
| NT 10-Q | Filing | May 15, 2024 | Mar 31, 2024 |
| SEC STAFF LETTER | Filing | May 10, 2024 | — |
| CORRESP | Letter to the SEC | Apr 30, 2024 | — |
| 425 | Filing | Apr 23, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2024 | — |
| 425 | Filing | Apr 3, 2024 | — |
| CORRESP | Letter to the SEC | Apr 2, 2024 | — |
| 425 | Filing | Mar 13, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 15, 2024 | — |
| 425 | Filing | Jan 22, 2024 | — |
| 425 | Filing | Jan 19, 2024 | — |
| 425 | Filing | Dec 12, 2023 | — |
| UPLOAD | Letter from the SEC | Dec 5, 2023 | — |
| CORRESP | Letter to the SEC | Dec 1, 2023 | — |
| NT 10-Q | Filing | Nov 14, 2023 | Sep 30, 2023 |
| 425 | Filing | Sep 21, 2023 | — |
| NT 10-Q | Filing | Aug 14, 2023 | Jun 30, 2023 |
| NT 10-Q | Filing | May 15, 2023 | Mar 31, 2023 |
| NT 10-K | Filing | Mar 31, 2023 | Dec 31, 2022 |
| UPLOAD | Letter from the SEC | Dec 12, 2022 | — |
| CORRESP | Letter to the SEC | Dec 1, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 16, 2022 | — |
| NT 10-Q | Filing | May 16, 2022 | Mar 31, 2022 |
| EFFECT | Filing | Jan 13, 2022 | — |
| CERT | Filing | Jan 13, 2022 | — |
| 8-A12B | Filing | Jan 13, 2022 | — |
| CORRESP | Letter to the SEC | Jan 12, 2022 | — |
| CORRESP | Letter to the SEC | Jan 12, 2022 | — |
| UPLOAD | Letter from the SEC | Dec 13, 2021 | — |
Showing 66 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ABPO (OTC), ABPWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1893219
- Former names
- Atlantic Coastal Acquisition Corp. II (until Nov 12, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.